Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients.

Paulussen, Michael; Ahrens, S.; Craft, A W; Dunst, Jürgen; Fröhlich, Birgit; Jabar, Susanne; Rübe, Christian; Winkelmann, W.; Wissing, S; Zoubek, A.; Jürgens, H.

doi:10.1200/jco.1998.16.9.3044

Cited by 223 publications

(132 citation statements)

References 23 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…The regimens that were applied are listed in Table 1. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] High-dose chemotherapy (HDC) with hematopoietic stem cell rescue was received by 51 patients, including 48 patients who received autologous peripheral blood stem cell transfusion (PBSCT) and 3 patients who underwent autologous bone marrow transplantation.…”

Section: Treatmentmentioning

confidence: 99%

Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan

Obata

Ueda

Kawai

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Ewing sarcoma family of tumors (ESFT) of bone is extremely rare in Japan. The objectives of the current study were to assess the clinical outcome and prognostic factors of patients with ESFT of bone in Japan and to compare them between Euro‐American and Japanese populations.METHODS.The authors conducted a retrospective analysis of 243 patients who were treated for ESFT of bone in Japan between 1981 and 2003. Local therapy was surgery in 35% of patients, surgery combined with radiotherapy in 40% of patients, radiotherapy alone in 22% of patients, and no local treatment in 3% of patients. All but 3 patients received various regimens of multidrug chemotherapy.RESULTS.The median patient age was 16 years. The primary disease sites were the trunk in 53% of patients and the extremities in 47% of patients. Forty‐one patients had metastases at presentation. The median follow‐up was 66 months. A univariate survival analysis demonstrated that patients who had metastases at presentation, primary site in the trunk, age ≥16 years, tumor size ≥10 cm, tumor that responded poorly to induction chemotherapy, and local treatment with radiotherapy alone had a significantly worse event‐free survival (EFS). A multivariate analysis further verified that the former 3 factors were significant adverse prognostic factors. Of 201 patients with localized disease, 45 patients who received current chemotherapy regimens that included ifosfamide and etoposide had a significantly better 5‐year EFS rate (67.6%) compared with other patients.CONCLUSIONS.The clinical outcome of patients with localized ESFT of bone in Japan has improved markedly with the use of current chemotherapy regimens that include ifosfamide and etoposide and has become comparable to the outcomes observed in other major series of Euro‐American patients. The prognostic factors are also almost identical. Cancer 2007 © 2007 American Cancer Society.

show abstract

Section: Treatmentmentioning

confidence: 99%

Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan

Obata

Ueda

Kawai

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] However, patients with bulky primary tumors, with multifocal or metastatic disease at presentation or with refractory or recurrent disease have a very poor prognosis, with only 10-30% survival rate at 3 years. [1][2][3][4] As some studies have shown that there is a positive linear relationship between the dose of cytoreductive agents and tumor response, 5 the approach of high-dose chemo-and/or radiation therapy followed by autologous hematopoietic SCT (HSCT) has been used in the practice of treatment of EFT in an attempt to improve the disease outcome and overall survival (OS) rate. We report our experience with further intensification of treatment in children and adolescents with high-risk EFT.…”

Section: Introductionmentioning

confidence: 99%

High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors

Rosenthal

Bolotin

Shakhnovits

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

The purpose of the study was to evaluate the feasibility and safety of two cycles of high-dose chemotherapy (HDT) followed by autologous hematopoietic SCT (HSCT) in patients with poor prognosis Ewing family of tumors (EFT). Twenty patients with primary metastatic bulky disease or recurrent EFT were enrolled to a treatment protocol with two cycles of HDT and HSCT. Patients tolerated well the first (n ¼ 20) and second (n ¼ 13) cycles, with limited and predictable toxicities. Only one (5%) TRM occurred during the second cycle. Myeloid engraftment occurred at the median of 11 days after both cycles. At 3 years, the overall and EFS were 45% (confidence interval; CI 0.22, 0.69) and 47% (CI 0.25, 0.70), respectively, for the entire group and 58% (CI 0.30, 0.86) for patients who completed two cycles. Dose intensification with two cycles of HDT and HSCT is feasible and safe, with low and acceptable treatmentrelated morbidity and mortality. Adding a second course of therapy does not impair engraftment. However, only 65% of the patients were able to proceed to the second cycle. Further studies are required to define the optimal mode of delivery of HDT and HSCT in treatment of advanced EFT.

show abstract

“…[67] Tüm akciğer radyoterapisi (Whole lung irradiation -WLI), sadece akciğerde metastazı olan hastalarda sağkalımı arttırır. [68] …”

Section: Lokalize Hastalıkta Tedavi Ve Radyoterapinin Yeriunclassified

Sık görülen primer malign kemik tümörlerinde radyoterapinin yeri ve tedaviye genel yaklaşım

Karakaya¹

2014

TOTBID

View full text Add to dashboard Cite

show abstract

Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients.

Abstract: Chemotherapy response of the primary tumor is a prognostic factor in patients with ET with ppm. Strategies of treatment intensification warrant further evaluation.

Cited by 223 publications

References 23 publications

Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan

Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan

High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors

Sık görülen primer malign kemik tümörlerinde radyoterapinin yeri ve tedaviye genel yaklaşım

Contact Info

Product

Resources

About